Adjuvant Hysterectomy for Cervical Cancer Patients Treated with Chemoradiation Therapy: A Systematic Review on the Pathology-Proven Residual Disease Rate.
adjuvant hysterectomy
chemoradiation therapy
complications
locally advanced cervical cancer
survival
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
08 Dec 2021
08 Dec 2021
Historique:
received:
07
11
2021
revised:
01
12
2021
accepted:
03
12
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
25
12
2021
Statut:
epublish
Résumé
To determine the incidence of pathology-proven residual disease in adjuvant hysterectomy specimens in patients with cervical cancer, treated with chemoradiation therapy. Secondly, to assess a possible association for pathology-proven residual disease regarding the time between chemoradiation therapy and adjuvant hysterectomy. Additionally, the survival rate and complication rate were assessed. PubMed, EMBASE, and the Cochrane database were searched from inception up to 8 March 2021. Of the 4601 screened articles, eleven studies were included. A total of 1205 patients were treated with chemoradiation therapy and adjuvant hysterectomy, ranging from three to twelve weeks after chemoradiation therapy. A total of 411 out of 1205 patients (34%) had pathology-proven residual disease in the adjuvant hysterectomy specimen. There was no association found in the time between chemoradiation therapy and adjuvant hysterectomy. Follow-up ranged from 2.4 to 245 months, during which 270 patients (22%) relapsed, and 298 patients (27%) were deceased. A total of 202 (35%) complications were registered in 578 patients. there is no association found in the time between chemoradiation therapy and residual disease on adjuvant hysterectomy specimens. The survival rates after chemoradiation therapy and adjuvant hysterectomy are suboptimal, while the risk of complications after adjuvant hysterectomy is high.
Identifiants
pubmed: 34944810
pii: cancers13246190
doi: 10.3390/cancers13246190
pmc: PMC8699574
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Anticancer Res. 2014 Jul;34(7):3861-6
pubmed: 24982415
Oncologist. 2010;15(4):405-15
pubmed: 20332143
Radiother Oncol. 2007 May;83(2):148-55
pubmed: 17531904
Gynecol Oncol. 2009 Sep;114(3):404-9
pubmed: 19555996
J Med Assoc Thai. 2005 Oct;88(10):1331-7
pubmed: 16519375
Radiother Oncol. 2016 Sep;120(3):428-433
pubmed: 27134181
J Gynecol Oncol. 2018 Mar;29(2):e25
pubmed: 29400018
Aust N Z J Obstet Gynaecol. 2010 Jun;50(3):289-93
pubmed: 20618249
Gynecol Oncol. 2020 Feb;156(2):328-334
pubmed: 31864683
World J Gastroenterol. 2006 Feb 21;12(7):1115-9
pubmed: 16534855
Int J Gynecol Cancer. 2018 May;28(4):641-655
pubmed: 29688967
Oncotarget. 2017 Dec 8;9(2):2866-2875
pubmed: 29416819
Gynecol Oncol. 1995 Nov;59(2):277-82
pubmed: 7590487
Oncologist. 2012;17(1):64-71
pubmed: 22234626
Int J Gynecol Cancer. 2014 Sep;24(7):1276-85
pubmed: 24987914
Radiographics. 2009 Jul-Aug;29(4):1073-83
pubmed: 19605657
Acta Obstet Gynecol Scand. 2021 Jul;100(7):1176-1185
pubmed: 33469927
N Engl J Med. 1999 Apr 15;340(15):1154-61
pubmed: 10202166
Cancer. 2014 Dec 15;120(24):3870-83
pubmed: 25056522
Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:22-36
pubmed: 30306584
BJOG. 2012 Nov;119(12):1447-54
pubmed: 22901248
Int J Gynaecol Obstet. 2014 May;125(2):111-5
pubmed: 24548892
World J Surg Oncol. 2009 Feb 16;7:19
pubmed: 19220882
Am J Obstet Gynecol. 2010 Oct;203(4):351.e1-8
pubmed: 20541170
Int J Med Sci. 2012;9(3):193-9
pubmed: 22408567
BMC Cancer. 2018 Mar 20;18(1):308
pubmed: 29558900
J Clin Oncol. 2004 Mar 1;22(5):872-80
pubmed: 14990643